Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study on the Efficacy and Safety of QLM1016 in Schizophrenia
Sponsor: Qilu Pharmaceutical Co., Ltd.
Summary
The study will evaluate the antipsychotic efficacy of QLM1016 in a multicenter, randomized, double-blind, parallel controlled study in patients diagnosed with schizophrenia.
Official title: A Multicenter, Randomized, Double-blind, Parallel Controlled Study on the Efficacy and Safety of QLM1016 in the Treatment of Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
402
Start Date
2025-10-02
Completion Date
2026-12
Last Updated
2026-10-14
Healthy Volunteers
No
Conditions
Interventions
3-6mg QLM1016
3-6mg QLM1016 pluse Aripiprazole dummy oral solution film administered orally once daily for 6 weeks
10-20 mg Aripiprazole oral solution film
10-20mg Aripiprazole oral solution film plus QLM1016 dummy oral solution film administered orally once daily for 6 weeks.
Locations (1)
No. 8888 Lvyou Road
Jinan, Shandong, China